Document:

EX-10.18

 Exhibit 10.18 
 BIOCEPT, INC. 
 NOTE AND WARRANT PURCHASE AGREEMENT 

THIS NOTE AND WARRANT PURCHASE
AGREEMENT (this “Agreement”) is made and entered into as of February 1, 2011 (the “Effective Date”) by and among BIOCEPT,
INC., a California corporation (the “Company”) and the Investors listed on the Schedule of Investors attached hereto (each an “Investor and collectively, the
“Investors”). 
 RECITALS 

WHEREAS, in exchange for a series of loans in an aggregate amount equal to
$5,000,000 from the Investors, the Company will issue secured convertible promissory notes and a warrant to purchase shares of the Company’s Preferred Stock (the “Preferred Stock”) to the Investors. 

AGREEMENT 
 NOW THEREFORE, the parties to this Agreement, for good and valuable consideration, the receipt and sufficiency of which is acknowledged and agreed,
hereby agree as follows: 
 1.        LOAN AMOUNT;
ISSUANCE OF NOTES AND WARRANT. 

1.1        Loan Amount; Issuance of Notes.    Subject
to the terms of this Agreement, the Investors agree, jointly and severally, to lend to the Company at each Closing (as defined below) the amount set forth on the Schedule of Investors attached hereto (each, a “Loan Amount”
and collectively the “Total Loan Amount” or “Loan”) against the issuance and delivery by the Company of convertible promissory notes for such amounts, in substantially the form attached hereto as
Exhibit A (each, a “Note” and collectively, the “Notes”). 
 1.2        Issuance of Warrants.    Subject to the terms of this Agreement, the Investors participating in each Closing agree to purchase
from the Company, and the Company agrees to issue to such Investors, a Warrant in the form attached hereto as Exhibit B (the “Warrant”) to purchase the number of shares of Preferred Stock set forth in the Warrant
(the “Warrant Shares”). 

1.3        Security Interest.    The payment
obligations evidenced by the Notes shall be secured by a security interest as described in the Notes and pursuant to a Subordinated Security Agreement in the form attached hereto as Exhibit C (the “Security
Agreement”). 
 2.        CLOSINGS;
DELIVERY. 
 2.1        Initial
Closing.    The initial closing of the purchase and sale of the Notes (the “Initial Closing”) shall be held on the date hereof at the offices of Cooley LLP, 4401 Eastgate Mall, San Diego, California
92121, or at such other time and place as the Company and the Investors mutually agree. 

  
 1. 

    (a)        Deliveries by the
Company.    At the Initial Closing, the Company shall deliver (a) a duly executed Note (in the principal amount set forth on the Schedule of Investors attached hereto under the heading “Initial Closing Principal
Amount of Note”) (b) a duly executed Warrant to purchase the Warrant Shares, and (c) the duly executed Security Agreement. 
     (b)        Deliveries by Investors.    At the Initial Closing, the Investor participating in the Initial Closing
shall deliver to the Company funds, by check or wire transfer, in the amount set forth opposite such Investor’s name on the Schedule of Investors attached hereto under the heading “Initial Closing Principal Amount of Note.”

 2.2        Second Closing.    On
March 1, 2011, the second closing of the purchase and sale of the Notes in the principal amounts set forth opposite each Investor’s name under the heading “Second Closing Principal Amount of Note” on the Schedule of Investors
attached hereto (the “Second Closing”) shall take place. 

    (a)        Deliveries by the
Company.    At the Second Closing, the Company shall deliver to each Investor participating in the Second Closing (a) a duly executed Note (in the principal amount set forth on the Schedule of Investors attached hereto
under the heading “Second Closing Principal Amount of Note”) and (b) a duly executed Warrant to purchase the Warrant Shares. 
     (b)        Deliveries by Investors.    At the Second Closing, the Investors shall, in the aggregate, deliver to
the Company funds, by check or wire transfer, in the amount set forth on the Schedule of Investors attached hereto under the heading “Second Closing Principal Amount of Note.” 

2.3        Third Closing.    On April 1, 2011,
the third closing of the purchase and sale of the Notes in the principal amounts set forth opposite each Investor’s name under the heading “Third Closing Principal Amount of Note” on the Schedule of Investors attached hereto (the
“Third Closing”) shall take place. 

    (a)        Deliveries by the
Company.    At the Third Closing, the Company shall deliver to each Investor participating in the Third Closing (a) a duly executed Note (in the principal amount set forth on the Schedule of Investors attached hereto
under the heading “Third Closing Principal Amount of Note”) and (b) a duly executed Warrant to purchase the Warrant Shares. 
     (b)        Deliveries by Investors.    At the Third Closing, the Investors shall, in the aggregate, deliver to
the Company funds, by check or wire transfer, in the amount set forth on the Schedule of Investors attached hereto under the heading “Third Closing Principal Amount of Note.” 

2.4        Fourth Closing.    On May 2, 2011, the
fourth closing of the purchase and sale of the Notes in the principal amounts set forth opposite each Investor’s name under the heading “Fourth Closing Principal Amount of Note” on the Schedule of Investors attached hereto (the
“Fourth Closing”) shall take place. 

  
 2. 

    (a)        Deliveries by the
Company.    At the Fourth Closing, the Company shall deliver to each Investor participating in the Fourth Closing (a) a duly executed Note (in the principal amount set forth on the Schedule of Investors attached hereto
under the heading “Fourth Closing Principal Amount of Note”) and (b) a duly executed Warrant to purchase the Warrant Shares. 
     (b)        Deliveries by Investors.    At the Fourth Closing, the Investors shall, in the aggregate, deliver to
the Company funds, by check or wire transfer, in the amount set forth on the Schedule of Investors attached hereto under the heading “Fourth Closing Principal Amount of Note.” 

2.5        Fifth Closing.    On June 1, 2011, the
fifth closing of the purchase and sale of the Notes in the principal amounts set forth opposite each Investor’s name under the heading “Fifth Closing Principal Amount of Note” on the Schedule of Investors attached hereto (the
“Fifth Closing” and each of the Fifth Closing, Fourth Closing, Third Closing, Second Closing and Initial Closing, a “Closing”) shall take place. 

    (a)        Deliveries by the
Company.    At the Fifth Closing, the Company shall deliver to each Investor participating in the Fifth Closing (a) a duly executed Note (in the principal amount set forth on the Schedule of Investors attached hereto
under the heading “Fifth Closing Principal Amount of Note”) and (b) a duly executed Warrant to purchase the Warrant Shares. 
     (b)        Deliveries by Investors.    At the Fifth Closing, the Investors shall, in the aggregate, deliver to
the Company funds, by check or wire transfer, in the amount set forth on the Schedule of Investors attached hereto under the heading “Fifth Closing Principal Amount of Note.” 

The issuance of the Notes and the Warrants to the Investors at each Closing, as applicable, shall be made on the terms
and conditions set forth in this Agreement, provided that (i) the representations and warranties of the Company set forth in Section 3 hereof shall speak as of the date of such Closing and (ii) the representations and warranties of
each Investor participating in such Closing set forth in Section 4 hereof shall speak as of the date of such Closing. 
  

	 3.
	 REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

 The Company hereby represents and warrants to each Investor, as of each Closing, as
applicable, as follows: 
 3.1        Organization and Standing;
Articles and Bylaws.    The Company is a corporation duly organized and validly existing under, and by virtue of, the laws of the State of California and is in good standing under such laws. The Company has the requisite
corporate power to own and operate its properties and assets, and to carry on its business as presently conducted and as proposed to be conducted. The Company is duly qualified and is authorized to transact business and is in good standing as a
foreign corporation in each jurisdiction in which 

  
 3. 

 
the failure to so qualify would have a material adverse effect on its business, properties, or financial condition. 

3.2        Corporate Power.    The Company will have
at each Closing all requisite legal and corporate power to execute and deliver this Agreement and to carry out and perform its obligations under the terms of this Agreement. 

3.3        Authorization.    All corporate action on
the part of the Company, its directors and its shareholders necessary for the authorization, execution, delivery and performance of this Agreement, the Notes, the Warrant and the Security Agreement (collectively, the “Loan
Documents”) by the Company and the performance of the Company’s obligations hereunder and thereunder, including the issuance and delivery of the Notes and Warrant and the reservation of the equity securities issuable upon
conversion of the Notes and exercise of the Warrant (collectively, the “Conversion Shares” and, together with the Notes and the Warrants, the “Securities”) has been taken or will be taken prior to the
issuance of such Securities, as applicable. The Loan Documents, when executed and delivered by the Company, shall constitute valid and binding obligations of the Company enforceable against the Company in accordance with their terms, except
(a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors’ rights, (b) as limited by general principles of equity that restrict the
availability of equitable remedies and (c) with respect to rights to indemnity, subject to federal and state securities laws. The Securities, when issued in compliance with the provisions of the Loan Documents, will be validly issued, fully
paid and nonassessable. The issuance of the Securities pursuant to the provisions of this Agreement will not violate any preemptive rights or rights of first refusal granted by the Company that will not be validly complied with or waived. The
Securities, when issued in compliance with the provisions of the Loan Documents, will be free of any liens or encumbrances, other than any liens or encumbrances created by or imposed upon the Investor through no action of the Company; provided,
however, that the Securities may be subject to restrictions on transfer under (i) that certain Investor Rights Agreement, by and among the Company and the other signatories thereto, dated August 4, 2010 (the “Investor Rights
Agreement”), (ii) the Company’s Bylaws and (iii) state and/or federal securities laws. 
 3.4        Governmental Consents.    All consents, approvals, orders, or authorizations of, or registrations, qualifications,
designations, declarations, or filings with, any governmental authority, required on the part of the Company in connection with the valid execution and delivery of the Loan Documents, the offer, sale or issuance of the Securities, or the
consummation of any other transaction contemplated hereby shall have been obtained and will be effective at the Initial Closing and at each subsequent Closing, except for notices required or permitted to be filed with certain state and federal
securities commissions, which notices will be filed on a timely basis. 

3.5        Offering.    Assuming the accuracy of the
representations and warranties of the Investor contained in Section 4 hereof, the offer, issue, and sale of the Notes and the Warrant are and will be exempt from the registration and prospectus delivery requirements of the Securities Act of
1933, as amended (the “Securities Act”), and have been registered or qualified (or are exempt from registration and qualification) under the registration, permit, or qualification requirements of all applicable state
securities laws. 

  
 4. 

	 4.
	 REPRESENTATIONS AND WARRANTIES OF THE INVESTOR.

 Each Investor hereby represents and warrants to the Company as of each Closing in which
such Investor participates, as applicable, as follows: 

4.1        Requisite Power and Authority.    The
Investor has all necessary power and authority to execute and deliver this Agreement and the Loan Documents and to carry out their provisions. All action on the Investor’s part required for the lawful execution and delivery of this Agreement
and the Loan Documents has been taken. Upon their execution and delivery, this Agreement and the Loan Documents will be valid and binding obligations of the Investor, enforceable against the Investor in accordance with their terms, except
(a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors’ rights, and (b) as limited by general principles of equity that restrict the
availability of equitable remedies. 
 4.2        Purchase for Own
Account.    The Investor represents that it is acquiring the Securities solely for its own account and beneficial interest for investment only, and not for sale or with a view to distribution of the Securities or any part
thereof, has no present intention of selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the same, and does not presently have reason to anticipate a change in such intention.

 4.3        Information and
Sophistication.    The Investor (i) acknowledges that it has received all the information that it or its qualified purchaser representative has requested from the Company and that it considers necessary or appropriate
for deciding whether to acquire the Securities, (ii) represents that it or its qualified purchaser representative has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of
the Securities and to obtain any additional information necessary to verify the accuracy of the information given the Investor and (iii) further represents that it has such knowledge and experience in financial and business matters that it is
capable of evaluating the merits and risk of this investment. Without limiting the foregoing, the Investor is relying on its own independent investigation of the Company and on its own respective professional advisors in entering into this Agreement
and consummating the transactions described herein. 

4.4        Ability to Bear Economic Risk.    The
Investor acknowledges that investment in the Securities involves a high degree of risk, and represents that it is able, without materially impairing its financial condition, to hold the Securities for an indefinite period of time and to suffer a
complete loss of its investment. 
 4.5        Further Limitations on
Disposition.    Without in any way limiting the representations set forth above, the Investor further agrees not to make any disposition of all or any portion of the Securities unless and until: 

    (a)        There is then in effect a registration
statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or 

  
 5. 

 (b)        (i) The
transferee has agreed in writing to be bound by the terms of this Agreement, (ii) the Investor shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances
surrounding the proposed disposition, and (iii) if reasonably requested by the Company, the Investor shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require
registration of such shares under the Securities Act. It is agreed that the Company will not require opinions of counsel for transactions made pursuant to Rule 144, except in unusual circumstances. The Company will not require the transferee to be
bound by the terms of this Agreement after the Company’s first firm commitment underwritten public offering of its Common Stock registered under the Securities Act (the “Initial Offering”). 

(c)        Notwithstanding the provisions of subsections (a) and
(b) above, no such restriction shall apply to a transfer by the Investor to an entity affiliated by common control (or other related entity) with the Investor (each such transferee, an “Affiliate” of the Investor);
provided that in each case the transferee will agree in writing to be subject to the terms of this Agreement to the same extent as if the transferee were an original Investor hereunder. 

(d)        Each certificate evidencing the Securities to be issued to the
Investor shall be stamped or otherwise imprinted with legends substantially similar to the following (in addition to any legend required under (i) the Investor Rights Agreement, (ii) the Company’s Bylaws and (iii) applicable
state securities laws): 
 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL
SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. 
 THE
SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT BY AND BETWEEN THE INVESTOR AND THE COMPANY. COPIES OF SUCH AGREEMENT
MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY. 

(e)        The Company shall be obligated to reissue promptly unlegended
certificates representing any Securities held by the Investor at the request of the Investor if the Company has completed its Initial Offering and the Investor has obtained an opinion of counsel (which counsel may be counsel to the Company)
reasonably acceptable to the Company to the effect that the securities proposed to be disposed of may lawfully be disposed of without registration, qualification and legend. 

  
 6. 

    (f)        Any legend endorsed on an instrument
pursuant to applicable state securities laws and the stop-transfer instructions with respect to such securities shall be removed upon receipt by the Company of an order of the appropriate state securities authority authorizing such removal.

 4.6        Accredited Investor
Status.    The Investor is an accredited investor or is represented by a purchaser representative within the meaning of Regulation D under the Securities Act. 

5.        FURTHER ASSURANCES.    The
Company and each Investor agree and covenant that at any time and from time to time it will promptly execute and deliver to each other such further instruments and documents and take such further action as each of the parties hereto may reasonably
require in order to carry out the full intent and purpose of this Agreement. 
  

	 6.
	 MISCELLANEOUS. 

 6.1        Binding Agreement.    The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the
respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any third party any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly
provided in this Agreement. 
 6.2        Governing
Law.    This Agreement shall be governed by and construed under the laws of the State of California as applied to agreements among California residents, made and to be performed entirely within the State of California without
giving effect to its conflicts of laws principles. 

6.3        Counterparts; Facsimile.    This Agreement
may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile signatures shall be as effective as original signatures. 

6.4        Expenses.    Each party shall pay all costs
and expenses that it incurs with respect to the negotiation, execution, delivery and performance of this Agreement and the transactions contemplated hereby. 
 6.5        Titles and Subtitles.    The titles and subtitles used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement. 

6.6        Notices.    All notices required or
permitted hereunder or under the Notes or the Warrant shall be in writing (including facsimile, electronic mail or similar electronic transmissions), and shall be deemed effectively given: (a) when received by the addressee, if delivered by
hand, facsimile, electronic mail or similar form of electronic transmission, (b) five days after mailing, if mailed by registered or certified mail, return receipt requested, postage prepaid or (c) one day after deposit with a nationally
recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent (i) to the Company at 5810 Nancy Ridge Drive, San Diego, California 92121, Attn: Meg McGilley, Facsimile No:
(858) 320-8261 or (ii) to the Investors at the address shown on the Schedule of 

  
 7. 

 
Investors, or at such other address as such party may designate by written notice to the other party. 
 6.7        Amendment; Waiver.    Except as otherwise set forth herein, no amendment or waiver of any provision of this Agreement shall be
effective unless in writing and approved by the Company and the holders of at least a majority in interest of the outstanding Securities. 
 6.8        Expenses.    Each party shall pay all costs and expenses that it incurs with respect to the negotiation, execution, delivery
and performance of this Agreement. 
 6.9        Delays or
Omissions.    It is agreed that no delay or omission to exercise any right, power or remedy accruing to any party, upon any breach, default or noncompliance by another party under this Agreement, the Notes or the Warrant,
shall impair any such right, power or remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance, or any acquiescence therein, or of or in any similar breach, default or noncompliance thereafter occurring. It is
further agreed that any waiver, permit, consent or approval of any kind or character on any party’s part of any breach, default or noncompliance under this Agreement, the Notes or the Warrant, or any waiver on such party’s part of any
provisions or conditions of this Agreement, the Notes or the Warrant must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies under this Agreement, the Notes or the Warrant, by law, or
otherwise afforded to any party, shall be cumulative and not alternative. 

6.10        Entire Agreement.    This Agreement and
the exhibits hereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and no party shall be liable or bound to any other in any manner by any representations, warranties, covenants and
agreements except as specifically set forth herein. 

6.11        California Corporate Securities
Law.    THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT
OF ANY PART OF THE CONSIDERATION THEREFOR PRIOR TO SUCH QUALIFICATION OR IN THE ABSENCE OF AN EXEMPTION FROM SUCH QUALIFICATION IS UNLAWFUL. PRIOR TO ACCEPTANCE OF SUCH CONSIDERATION BY THE COMPANY, THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE
EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED OR AN EXEMPTION FROM SUCH QUALIFICATION BEING AVAILABLE. 

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 8. 

 IN WITNESS WHEREOF, the
parties have executed this NOTE AND WARRANT PURCHASE AGREEMENT as of the date first written above. 

 

			
	 COMPANY:

 
 BIOCEPT,
INC.,
 a California corporation

		
	 By:
	 	 /s/ Faye Wilson

		 	 Faye Wilson
 Lead Director

  
  
  

 
  
  

 
  

[SIGNATURE PAGE TO NOTE AND WARRANT
PURCHASE AGREEMENT] 

 IN WITNESS WHEREOF, the
parties have executed this NOTE AND WARRANT PURCHASE AGREEMENT as of the date first written above. 

 

			
	 THE REISS FAMILY GST EX
MARITAL
 DEDUCTION TRUST UDT 12/19/1988:

		
	 By: 
	 	 /s/ Claire K.T. Reiss

 
			
		
	 Name: 
	 	 Claire K.T. Reiss

 
			
		
	 Title: 
	 	 Trustee

  

			
	 THE REISS FAMILY
SURVIVOR’S TRUST
 UDT DATED
DECEMBER 19, 1988:

		
	 By: 
	 	 /s/ Claire K.T. Reiss

 
			
		
	 Name: 
	 	 Claire K.T. Reiss

 
			
		
	 Title: 
	 	 Trustee

  
  
  

 
  
  

 
  

[SIGNATURE PAGE TO NOTE AND WARRANT
PURCHASE AGREEMENT] 

 SCHEDULE OF INVESTORS 

 

											
	 INVESTOR NAME
	 	INITIAL CLOSING
PRINCIPAL
AMOUNT 
OF NOTE	 	SECOND CLOSING
PRINCIPAL
AMOUNT 
OF NOTE	 	THIRD CLOSING
PRINCIPAL
AMOUNT 
OF
NOTE	 	FOURTH 
CLOSING
PRINCIPAL
AMOUNT OF NOTE	 	FIFTH CLOSING
PRINCIPAL
AMOUNT 
OF NOTE
						
	 The Reiss Family GST
 Exempt Marital Deduction
 Trust
	 	$1,000,000	 	To be determined	 	To be determined	 	To be determined	 	To be determined
						
	 Address:
 9675 La Jolla Farms Road
 La Jolla, CA 92037
	 		 		 		 		 	
						
	 The Reiss Family
 Survivor’s Trust UDT
 dated December 19, 1988
	 	$0	 	To be determined	 	To be determined	 	To be determined	 	To be determined
						
	 Address:
 9675 La Jolla Farms Road
 La Jolla, CA 92037
	 	$0	 	To be determined	 	To be determined	 	To be determined	 	To be determined
		 	  

	 TOTAL:
	 	$1,000,000	 	$1,000,0001	 	$1,000,0001	 	$1,000,0001	 	$1,000,0001

  
  
  

 
  
  

 
 1 $1,000,000 in the aggregate to be lent by The Reiss Family GST Exempt
Marital Deduction Trust and/or The Reiss Family Survivor’s Trust UDT dated December 19, 1988. 

 EXHIBIT A 

FORM OF SECURED CONVERTIBLE PROMISSORY NOTE 

 EXHIBIT B 

FORM OF WARRANT 

 EXHIBIT C 

FORM OF SECURITY AGREEMENT 

 SUBORDINATED SECURITY AGREEMENT 

THIS SUBORDINATED SECURITY AGREEMENT
dated as of February 1, 2011 (“Security Agreement”), is made by BIOCEPT, INC., a California corporation
(“Grantor”), in favor of THE REISS FAMILY GST EXEMPT MARITAL DEDUCTION TRUST and
THE REISS FAMILY SURVIVOR’S TRUST UDT DATED DECEMBER 19, 1988 (each, a “Secured
Party”). 
 RECITALS 

A.        Each Secured Party has made and has
agreed to make certain advances of money and to extend certain financial accommodations to Grantor as evidenced by that certain Secured Convertible Promissory Note dated February 1, 2011 executed by Grantor in favor of Secured Party and such
other Secured Convertible Promissory Notes which may be executed by Grantor in favor of Secured Party after the date hereof (individually, the “Note” and, collectively, the “Notes”) and that certain
Note and Warrant Purchase Agreement dated February 1, 2011, by and between Grantor and each Secured Party (the “Purchase Agreement”), such advances, future advances, and financial accommodations being referred to herein
as the “Loans”. 

B.        Each Secured Party is willing to make the Loans to Grantor, but
only upon the condition, among others, that Grantor shall have executed and delivered to Secured Party this Security Agreement. 
 AGREEMENT 
 NOW,
THEREFORE, in order to induce Secured Party to make the Loans and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, and intending to be legally bound, Grantor
hereby represents, warrants, covenants and agrees as follows: 

1.        DEFINED TERMS. When
used in this Security Agreement the following terms shall have the following meanings (such meanings being equally applicable to both the singular and plural forms of the terms defined): 

“Bankruptcy Code” means Title XI of the United States Code. 

“Collateral” shall have the meaning assigned to such term in
Section 2 of this Security Agreement. 
 “Contracts” means all
contracts (including any customer, vendor, supplier, service or maintenance contract), leases, licenses, undertakings, purchase orders, permits, franchise agreements or other agreements (other than any right evidenced by Chattel Paper, Documents or
Instruments), whether in written or electronic form, in or under which Grantor now holds or hereafter acquires any right, title or interest, including, without limitation, with respect to an Account, any agreement relating to the terms of payment or
the terms of performance thereof. 
 “Copyright License” means any agreement, whether in
written or electronic form, in which Grantor now holds or hereafter acquires any interest, granting any right in or to any 

  
 1. 

 
Copyright or Copyright registration (whether Grantor is the licensee or the licensor thereunder) including, without limitation, licenses pursuant to which Grantor has obtained the exclusive right
to use a copyright owned by a third party. 
 “Copyrights” means all of
the following now owned or hereafter acquired or created (as a work for hire for the benefit of Grantor) by Grantor or in which Grantor now holds or hereafter acquires or receives any right or interest, in whole or in part: (a) all copyrights,
whether registered or unregistered, held pursuant to the laws of the United States, any State thereof or any other country; (b) registrations, applications, recordings and proceedings in the United States Copyright Office or in any similar
office or agency of the United States, any State thereof or any other country; (c) any continuations, renewals or extensions thereof; (d) any registrations to be issued in any pending applications, and shall include any right or interest
in and to work protectable by any of the foregoing which are presently or in the future owned, created or authorized (as a work for hire for the benefit of Grantor) or acquired by Grantor, in whole or in part; (e) prior versions of works
covered by copyright and all works based upon, derived from or incorporating such works; (f) income, royalties, damages, claims and payments now and hereafter due and/or payable with respect to copyrights, including, without limitation,
damages, claims and recoveries for past, present or future infringement; (g) rights to sue for past, present and future infringements of any copyright; and (h) any other rights corresponding to any of the foregoing rights throughout the
world. 
 “Event of Default” any “Event of
Default” as defined in the Notes. 
 “Intellectual Property” means any intellectual
property, in any medium, of any kind or nature whatsoever, now or hereafter owned or acquired or received by Grantor or in which Grantor now holds or hereafter acquires or receives any right or interest, and shall include, in any event, any
Copyright, Copyright License, Trademark, Trademark License, Patent, Patent License, trade secret, customer list, marketing plan, internet domain name (including any right related to the registration thereof), proprietary or confidential information,
mask work, source, object or other programming code, invention (whether or not patented or patentable), technical information, procedure, design, knowledge, know-how, software, data base, data, skill,
expertise, recipe, experience, process, model, drawing, material or record. 
 “License”
means any Copyright License, Patent License, Trademark License or other license of rights or interests, whether in-bound or out-bound, whether in written or electronic form, now or hereafter owned or acquired or received by Grantor or in which
Grantor now holds or hereafter acquires or receives any right or interest, and shall include any renewals or extensions of any of the foregoing thereof. 
 “Lien” means any mortgage, lien, deed of trust, charge, pledge, security interest or other encumbrance. 

“Money” means a medium of exchange authorized or adopted by a domestic or foreign government and
includes a monetary unit of account established by an intergovernmental organization or by agreement between two or more nations. 

  
 2. 

 “Patent License” means any agreement, whether in
written or electronic form, in which Grantor now holds or hereafter acquires any interest, granting any right with respect to any invention on which a Patent is in existence (whether Grantor is the licensee or the licensor thereunder). 

“Patents” means all of the following in which Grantor now holds or hereafter acquires any
interest: (a) all letters patent of the United States or any other country, all registrations and recordings thereof and all applications for letters patent of the United States or any other country, including, without limitation,
registrations, recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country; (b) all reissues, divisions, continuations, renewals,
continuations-in-part or extensions thereof; (c) all petty patents, divisionals and patents of addition; (d) all patents to issue in any such applications; (e) income, royalties, damages, claims and payments now and hereafter due
and/or payable with respect to patents, including, without limitation, damages, claims and recoveries for past, present or future infringement; and (f) rights to sue for past, present and future infringements of any patent. 

“Permitted Lien” means: (a) any Liens existing on the date of this Security Agreement and
set forth on Schedule A attached hereto; (b) Liens for taxes, fees, assessments or other governmental charges or levies, either not delinquent or being contested in good faith by appropriate proceedings; (c) Liens (i) upon or
in any Equipment acquired or held by Grantor to secure the purchase price of such Equipment or indebtedness (including capital leases) incurred solely for the purpose of financing the acquisition of such Equipment or (ii) existing on such
Equipment at the time of its acquisition, provided that the Lien is confined solely to the Equipment so acquired, improvements thereon and the Proceeds of such Equipment; (d) leases or subleases and licenses or sublicenses granted to others in
the ordinary course of Grantor’s business if such are not otherwise prohibited under this Security Agreement and do not interfere in any material respect with the business of Grantor; (e) any right, title or interest of a licensor under a
license; (f) Liens arising from judgments, decrees or attachments to the extent and only so long as such judgment, decree or attachment has not caused or resulted in an Event of Default; (g) easements, reservations, rights-of-way,
restrictions, minor defects or irregularities in title and other similar Liens affecting real property not interfering in any material respect with the ordinary conduct of the business of Grantor; (h) Liens in favor of customs and revenue
authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods; (i) Liens arising solely by virtue of any statutory or common law provision relating to banker’s liens, rights of
setoff or similar rights and remedies as to deposit accounts or other funds maintained with a creditor depository institution; (j) Liens in favor of a depository bank or a securities intermediary pursuant to such depository bank’s or
securities intermediary’s customary customer account agreement; provided that any such Liens shall at no time secure any indebtedness or obligations other than customary fees and charges payable to such depository bank or securities
intermediary; (k) statutory or common law Liens of landlords and carriers, warehousemen, mechanics, suppliers, materialmen, repairmen and other similar Liens, arising in the ordinary course of business and securing obligations that are not yet
delinquent or are being contested in good faith by appropriate proceedings; (l) Liens incurred or deposits made to secure the performance of tenders, bids, leases, statutory or regulatory obligations, surety and appeal bonds, government
contracts, performance and return-of-money bonds, and other obligations of like nature, in each case, in the ordinary course of business; (m) Liens incurred or deposits made 

  
 3. 

 
in the ordinary course of business in connection with workers’ compensation, unemployment insurance and other types of social security; (n) pledges and deposits securing liability for
reimbursement or indemnification obligations in respect of letters of credit or bank guarantees for the benefit of landlords; and (o) Liens incurred in connection with the extension, renewal or refinancing of indebtedness secured by Liens
permitted under the preceding clauses, provided that any extension, renewal or replacement Lien shall be limited to the property encumbered by the existing Lien and the principal amount of the indebtedness being extended, renewed or refinanced does
not increase. 
 “Secured Obligations” means (a) the obligation of Grantor to repay
Secured Party all of the unpaid principal amount of, and accrued interest on (including any interest that accrues after the commencement of bankruptcy), the Loans, and (b) the obligation of Grantor to pay any fees, costs and expenses of Secured
Party under the Notes, the Purchase Agreement, or this Security Agreement. 
 “Security
Agreement” means this Security Agreement and all Schedules hereto, as the same may from time to time be amended, modified, supplemented or restated. 

“Senior Indebtedness” shall mean the principal of, unpaid interest on and amounts reimbursable,
fees, expenses, costs of enforcement and other amounts due in connection with (a) those certain Secured Convertible Promissory Notes executed by Grantor in favor of The Reiss Family GST Exempt Marital Deduction Trust on December 22, 2008,
(b) that certain Note and Warrant Purchase Agreement dated December 22, 2008, by and between Grantor and The Reiss Family GST Exempt Marital Deduction Trust, and (c) that certain Amended and Restated Loan Agreement, pursuant to which
Goodman Co. Ltd. has loaned Grantor an aggregate of $3,000,000. 
 “Trademark License”
means any agreement, whether in written or electronic form, in which Grantor now holds or hereafter acquires any interest, granting any right in and to any Trademark or Trademark registration (whether Grantor is the licensee or the licensor
thereunder). 
 “Trademarks” means any of the following in which Grantor now holds or
hereafter acquires any interest: (a) any trademarks, tradenames, corporate names, company names, business names, trade styles, service marks, logos, other source or business identifiers, prints and labels on which any of the foregoing have
appeared or appear, designs and general intangibles of like nature, now existing or hereafter adopted or acquired, all registrations and recordings thereof and any applications in connection therewith, including, without limitation, registrations,
recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United States, any State thereof or any other country (collectively, the “Marks”); (b) any reissues, extensions or
renewals thereof; (c) the goodwill of the business symbolized by or associated with the Marks; (d) income, royalties, damages, claims and payments now and hereafter due and/or payable with respect to the Marks, including, without
limitation, damages, claims and recoveries for past, present or future infringement; and (e) rights to sue for past, present and future infringements of the Marks. 

  
 4. 

 “UCC” means the Uniform Commercial Code as the same
may from time to time be in effect in the State of California (and each reference in this Security Agreement to an Article thereof (denoted as a Division of the UCC as adopted and in effect in the State of California) shall refer to that
Article (or Division, as applicable) as from time to time in effect); provided, however, in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of Secured Party’s security
interest in any Collateral is governed by the Uniform Commercial Code as in effect in a jurisdiction other than the State of California, the term “UCC” shall mean the Uniform Commercial Code (including the Articles thereof) as in
effect at such time in such other jurisdiction for purposes of the provisions hereof relating to such attachment, perfection or priority and for purposes of definitions related to such provisions. 

In addition, the following terms shall be defined terms having the meaning set forth for such terms in the UCC:
“Account”, “Account Debtor”, “Chattel Paper”, “Commodity Account”, “Deposit Account”, “Documents”, “Equipment”, “Fixtures”, “General Intangible”,
“Goods”, “Instrument”, “Inventory”, “Investment Property”, “Letter-of-Credit Right”, “Money”, “Payment Intangibles”, “Proceeds”, “Promissory Notes”,
“Securities Account”, and “Supporting Obligations”. Each of the foregoing defined terms shall include all of such items now owned, or hereafter acquired, by Grantor. 

2.         GRANT OF SECURITY
INTEREST. Subject to Section 7, as collateral security for the full, prompt, complete and final payment and performance when due (whether at stated maturity, by acceleration or otherwise) of all the
Secured Obligations and in order to induce Secured Party to cause the Loans to be made, Grantor hereby assigns, conveys, mortgages, pledges, hypothecates and transfers to Secured Party, and hereby grants to Secured Party, a security interest in all
of Grantor’s right, title and interest in, to and under the following, whether now owned or hereafter acquired (all of which being collectively referred to herein as the “Collateral”): 

(a)        All Accounts of Grantor; 

(b)        All Chattel Paper of Grantor; 

(c)        All Commodity Accounts of Grantor; 

(d)        All Contracts of Grantor; 

(e)        All Deposit Accounts of Grantor; 

(f)        All Documents of Grantor; 

(g)        All General Intangibles of Grantor, including, without
limitation, Intellectual Property; 
 (h)        All Goods of
Grantor, including, without limitation, Equipment, Inventory and Fixtures; 

  
 5. 

 (i)         All Instruments
of Grantor, including, without limitation, Promissory Notes; 

(j)         All Investment Property of Grantor; 

(k)        All Letter-of Credit Rights of Grantor; 

(l)         All Money of Grantor; 

(m)       All Securities Accounts of Grantor; 

(n)        All Supporting Obligations of Grantor; 

(o)        All property of Grantor held by Secured Party, or any other
party for whom Secured Party is acting as agent, including, without limitation, all property of every-description now or hereafter in the possession or custody of or in transit to Secured Party or such other party for any purpose, including, without
limitation, safekeeping, collection or pledge, for the account of Grantor, or as to which Grantor may have any right or power; 
 (p)        All other goods and personal property of Grantor, wherever located, whether tangible or intangible, and whether now owned or hereafter acquired,
existing, leased or consigned by or to Grantor; and 

(q)        To the extent not otherwise included, all Proceeds of each of
the foregoing and all accessions to, substitutions and replacements for and rents, profits and products of each of the foregoing. 
 Notwithstanding the foregoing provisions of this Section 2, the grant, assignment and transfer of a security interest as provided herein shall not extend to, and the term
“Collateral” shall not include: (a) the collateral which is subject to the Liens set forth on Schedule A attached hereto, excluding (i) the collateral subject to the terms of that certain Security Agreement dated
December 22, 2008 granted to The Reiss Family GST Exempt Marital Deduction Trust and (ii) the collateral subject to the terms of that certain Subordinated Security Agreement granted to Goodman Co. Ltd., (b) “intent-to-use”
trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise or (c) any Account, Chattel Paper,
General Intangible or Promissory Note in which Grantor has any right, title or interest if and to the extent such Account, Chattel Paper, General Intangible or Promissory Note includes a provision containing a restriction on assignment such that the
creation of a security interest in the right, title or interest of Grantor therein would be prohibited and would, in and of itself, cause or result in a default thereunder enabling another person party to such Account, Chattel Paper, General
Intangible or Promissory Note to enforce any remedy with respect thereto; provided that the foregoing exclusion shall not apply if (i) such prohibition has been waived or such other person has otherwise consented to the creation
hereunder of a security interest in such Account, Chattel Paper, General Intangible or Promissory Note or (ii) such prohibition would be rendered ineffective pursuant to Sections 9-406(d), 9-407(a) or 9-408(a) of the UCC, as applicable and as
then in effect in any relevant jurisdiction, or any other applicable law (including the Bankruptcy Code) or principles of equity); provided further that immediately upon the ineffectiveness, lapse

  
 6. 

 
or termination of any such provision, the Collateral shall include, and Grantor shall be deemed to have granted on the date hereof a security interest in, all its rights, title and interests in
and to such Account, Chattel Paper, General Intangible or Promissory Note as if such provision had never been in effect; and provided further that the foregoing exclusion shall in no way be construed so as to limit, impair or otherwise affect
Secured Party’s unconditional continuing security interest in and to all rights, title and interests of Grantor in or to any payment obligations or other rights to receive monies due or to become due under any such Account, Chattel Paper,
General Intangible or Promissory Note and in any such monies and other proceeds of such Account, Chattel Paper, General Intangible or Promissory Note. 
 3.        RIGHTS OF SECURED PARTY; COLLECTION OF
ACCOUNTS. 
 (a)        Notwithstanding
anything contained in this Security Agreement to the contrary, Grantor expressly agrees that it shall remain liable under each of its Contracts, Chattel Paper, Documents, Instruments and Licenses to observe and perform all the conditions and
obligations to be observed and performed by it thereunder and that it shall perform all of its duties and obligations thereunder, all in accordance with and pursuant to the terms and provisions of each such Contract, Chattel Paper, Document,
Instrument or License. Secured Party shall not have any obligation or liability under any such Contract, Chattel Paper, Document, Instrument, or License by reason of or arising out of this Security Agreement or the granting to Secured Party of a
lien therein or the receipt by Secured Party of any payment relating to any such Contract, Chattel Paper, Document, Instrument, or License pursuant hereto, nor shall Secured Party be required or obligated in any manner to perform or fulfill any of
the obligations of Grantor under or pursuant to any such Contract, Chattel Paper, Document, Instrument, or License, or to make any payment, or to make any inquiry as to the nature or the sufficiency of any payment received by it or the sufficiency
of any performance by any party under any such Contract, Chattel Paper, Document, Instrument, or License, or to present or file any claim, or to take any action to collect or enforce any performance or the payment of any amounts which may have been
assigned to it or to which it may be entitled at any time or times. 

(b)        Secured Party authorizes Grantor to collect its Accounts.
Subject to the limitations set forth in Section 7, at the request of Secured Party, Grantor shall deliver all original and other documents evidencing and relating to the performance of labor or service which created such Accounts,
including, without limitation, all original orders, invoices and shipping receipts. 

(c)        Subject to the limitations set forth in Section 7,
Secured Party may at any time, upon the occurrence and during the continuance of any Event of Default, notify Account Debtors of Grantor, parties to the Contracts of Grantor, and obligors in respect of Instruments of Grantor and obligors in respect
of Chattel Paper of Grantor that the Accounts and the right, title and interest of Grantor in and under such Contracts, Instruments and Chattel Paper have been assigned to Secured Party and that payments shall be made directly to Secured Party.
Subject to the limitations set forth in Section 7, upon the occurrence and during the continuance of any Event of Default, upon the request of Secured Party, Grantor shall so notify such Account Debtors, parties to such Contracts,
obligors in respect of such Instruments and obligors in respect of such Chattel Paper. Secured Party may, in its name or in the name of others, communicate with such Account Debtors, parties to such Contracts, obligors in respect of such Instruments
and 

  
 7. 

 
obligors in respect of such Chattel Paper to verify with such parties, to Secured Party’s satisfaction, the existence, amount and terms of any such Accounts, Contracts, Instruments or
Chattel Paper. 
 4.        REPRESENTATIONS
AND WARRANTIES. Grantor hereby represents and warrants to Secured Party that: 
 (a)        Except for the security interest granted to Secured Party under this Security Agreement and Permitted Liens, Grantor is the sole legal and
equitable owner of each item of the Collateral in which it purports to grant a security interest hereunder. 

(b)        No effective security agreement, financing statement,
equivalent security or lien instrument or continuation statement covering all or any part of the Collateral exists, except such as may have been filed by Grantor in favor of Secured Party pursuant to this Security Agreement and except for Permitted
Liens. 
 (c)        This Security Agreement creates a legal and
valid security interest on and in all of the Collateral in which Grantor now has rights. 

(d)        Grantor’s taxpayer identification number is set forth in
the signature page hereof. Grantor’s chief executive office, principal place of business, and the place where Grantor maintains its records concerning the Collateral are presently located at the address set forth on the signature page hereof.
The Collateral consisting of goods, other than motor vehicles and such other mobile goods, is presently located at such address and at such additional addresses set forth on Schedule B attached hereto. 

(e)        All Collateral of Grantor consisting of Chattel Paper,
Instruments or Investment Property is set forth on Schedule C attached hereto. 

(f)        The name and address of each depository institution at which
Grantor maintains any Deposit Account and the account number and account name of each such Deposit Account is listed on Schedule D attached hereto. The name and address of each securities intermediary or commodity intermediary at which
Grantor maintains any Securities Account or Commodity Account and the account number and account name is listed on Schedule D attached hereto. Grantor agrees to amend Schedule D upon Secured Party’s request to reflect the opening
of any additional Deposit Account, Securities Account or Commodity Account, or closing or changing the account name or number on any existing Deposit Account, Securities Account, or Commodity Account. 

(g)        All Intellectual Property now owned or held by the Grantor are
listed on Schedule E attached hereto. 

5.        COVENANTS. Unless Secured Party
otherwise consents (which consent shall not be unreasonably withheld), Grantor covenants and agrees with Secured Party that from and after the date of this Security Agreement and until the Secured Obligations have been performed and paid in full
(other than inchoate indemnity obligations) and any commitment of Secured Party to make Loans to Grantor has expired or terminated: 

  
 8. 

 5.1        Disposition of
Collateral. Subject to Section 7, Grantor shall not sell, lease, transfer or otherwise dispose of any of the Collateral (each, a “Transfer”), or attempt or contract to do so, other than (a) the sale of
Inventory in the ordinary course of business, (b) the granting of Licenses in the ordinary course of business and (c) the disposal of worn-out or obsolete Equipment. 

5.2        Change of Jurisdiction of Organization, Relocation of
Business. Grantor shall not change its jurisdiction of organization or relocate its chief executive office, principal place of business or its records from such address(es) provided to Secured Party pursuant to Section 4(d) above
without at least seven (7) days prior notice to Secured Party. 

5.3        Limitation on Liens on Collateral. Grantor shall not, directly
or indirectly, create, permit or suffer to exist, and shall defend the Collateral against and take such other action as is necessary to remove, any Lien on the Collateral, except (a) Permitted Liens and (b) the Lien granted to Secured
Party under this Security Agreement. 
 5.4        Insurance.
Grantor shall maintain insurance policies insuring the Collateral against loss or damage from such risks and in such amounts and forms and with such companies as are customarily maintained by businesses similar to Grantor. 

5.5        Taxes, Assessments, Etc. Grantor shall pay promptly when due
all property and other taxes, assessments and government charges or levies imposed upon, and all claims (including claims for labor, materials and supplies) against, the Goods, except to the extent the validity or amount thereof is being contested
in good faith and adequate reserves are being maintained in connection therewith. 

5.6        Defense of Intellectual Property. Grantor shall use
commercially reasonable efforts to (i) protect, defend and maintain the validity and enforceability of all Copyrights, Patents and Trademarks material to Grantor’s business and (ii) detect infringements of all Copyrights, Patents and
Trademarks material to Grantor’s business. 

5.7        Further Assurances. At any time and from time to time, upon
the written request of Secured Party, and at the sole expense of Grantor, Grantor shall promptly and duly execute and deliver any and all such further instruments and documents and take such further action as Secured Party may reasonably deem
necessary or desirable to obtain the full benefits of this Security Agreement, including, without limitation, (a) executing, delivering and causing to be filed any financing or continuation statements (including “in lieu” continuation
statements) under the UCC with respect to the security interests granted hereby, (b) at Secured Party’s reasonable request, filing or cooperating with Secured Party in filing any forms or other documents required to be recorded with the
United States Patent and Trademark Office, United States Copyright Office, (c) at Secured Party’s reasonable request, placing the interest of Secured Party as lienholder on the certificate of title (or similar evidence of ownership) of any
vehicle, watercraft or other Equipment constituting Collateral owned by Grantor which is covered by a certificate of title (or similar evidence of ownership), (d) executing and delivering and using commercially reasonable efforts to cause the
applicable depository institution, securities intermediary, commodity intermediary or issuer or nominated party under a letter of credit to execute and deliver a collateral control agreement with respect to any Deposit Account,

  
 9. 

 
Securities Account or Commodity Account or Letter-of-Credit Right in or to which Grantor has any right or interest and (e) at Secured Party’s reasonable request, using commercially
reasonable efforts to obtain acknowledgments from bailees having possession of any Collateral and waivers of liens from landlords and mortgagees of any location where any of the Collateral may from time to time be stored or located. Grantor also
hereby authorizes Secured Party to file any such financing or continuation statement (including “in lieu” continuation statements) without the signature of Grantor. 

6.        SECURED PARTY’S
APPOINTMENT AS ATTORNEY-IN-FACT; PERFORMANCE BY SECURED PARTY. 

(a)        Subject to Section 6(b) and Section 7,
Grantor hereby irrevocably constitutes and appoints Secured Party, and any officer or agent of Secured Party, with full power of substitution, as its true and lawful attorney-in-fact with full, irrevocable power and authority in the place and stead
of Grantor and in the name of Grantor or in its own name, from time to time at Secured Party’s discretion, for the purpose of carrying out the terms of this Security Agreement, to take any and all appropriate action and to execute and deliver
any and all documents and instruments which may be necessary or desirable to accomplish the purposes of this Security Agreement and, without limiting the generality of the foregoing, hereby gives Secured Party the power and right, on behalf of
Grantor, without notice to or assent by Grantor to do the following: 

(i)        to ask, demand, collect, receive and give acquittances and
receipts for any and all monies due or to become due under any Collateral and, in the name of Grantor, in its own name or otherwise to take possession of, endorse and collect any checks, drafts, notes, acceptances or other Instruments for the
payment of monies due under any Collateral and to file any claim or take or commence any other action or proceeding in any court of law or equity or otherwise deemed appropriate by Secured Party for the purpose of collecting any and all such monies
due under any Collateral whenever payable; 
 (ii)        to pay
or discharge any Liens, including, without limitation, any tax lien, levied or placed on or threatened against the Collateral, to effect any repairs or any insurance called for by the terms of this Security Agreement and to pay all or any part of
the premiums therefor and the costs thereof, which actions shall be for the benefit of Secured Party and not Grantor; 
 (iii)        to (1) direct any person liable for any payment under or in respect of any of the Collateral to make payment of any and all monies due or
to become due thereunder directly to Secured Party or as Secured Party shall direct, (2) receive payment of any and all monies, claims and other amounts due or to become due at any time arising out of or in respect of any Collateral,
(3) sign and endorse any invoices, freight or express bills, bills of lading, storage or warehouse receipts, drafts against debtors, assignments, verifications and notices in connection with Accounts and other Instruments and Documents
constituting or relating to the Collateral, (4) commence and prosecute any suits, actions or proceedings at law or in equity in any court of competent jurisdiction to collect the Collateral or any part thereof and to enforce any other right in
respect of any Collateral, (5) defend any suit, action or proceeding brought against Grantor with respect to any Collateral, (6) settle, compromise or adjust any suit, 

  
 10.

 
action or proceeding described above, and in connection therewith, give such discharges or releases as Secured Party may deem appropriate, (7) license, or, to the extent permitted by an
applicable License, sublicense, whether general, special or otherwise, and whether on an exclusive or non-exclusive basis, any Copyright, Patent or Trademark throughout the world for such term or terms, on such conditions and in such manner as
Secured Party shall in its discretion determine and (8) sell, transfer, pledge, make any agreement with respect to or otherwise deal with any of the Collateral as fully and completely as though Secured Party were the absolute owner thereof for
all purposes; and 
 (iv)        to do, at Secured Party’s
option and Grantor’s expense, at any time, or from time to time, all acts and things which Secured Party may reasonably deem necessary to protect, preserve or realize upon the Collateral and Secured Party’s security interest therein in
order to effect the intent of this Security Agreement, all as fully and effectively as Grantor might do. 

(b)        Secured Party agrees that, subject to the limitations set
forth in Section 7 and except upon the occurrence and during the continuation of an Event of Default, it shall not exercise the power of attorney or any rights granted to Secured Party pursuant to this Section 6. Grantor
hereby ratifies, to the extent permitted by law, all that said attorney shall lawfully do or cause to be done by virtue hereof. The power of attorney granted pursuant to this Section 6 is a power coupled with an interest and shall be
irrevocable until the Secured Obligations are completely and indefeasibly paid and performed in full and Secured Party no longer has any commitment to make any Loans to Grantor. 

(c)        If Grantor fails to perform or comply with any of its
agreements contained herein and Secured Party, as provided for by the terms of this Security Agreement, shall perform or comply, or otherwise cause performance or compliance, with such agreement, the reasonable expenses, including reasonable
attorneys’ fees and costs, of Secured Party together with interest thereon at a rate of interest equal to the highest per annum rate of interest charged on the Loans, incurred in connection with such performance or compliance, shall be payable
by Grantor to Secured Party within five (5) business days of demand and shall constitute Secured Obligations secured hereby. 
 7.        SUBORDINATION. The indebtedness evidenced by the Notes is hereby expressly subordinated, to the extent and in the manner hereinafter
set forth, in right of payment to the prior payment in full of the Senior Indebtedness. 

7.1        Insolvency Proceedings. If there shall occur any receivership,
insolvency, assignment for the benefit of creditors, bankruptcy, reorganization, or arrangements with creditors (whether or not pursuant to bankruptcy or other insolvency laws), sale of all or substantially all of the assets, dissolution,
liquidation, or any other marshaling of the assets and liabilities of Grantor, (a) no amount shall be paid by Grantor in respect of the principal of, interest on or other amounts due with respect to the Notes or the Loans at the time
outstanding, unless and until the principal of and interest on the Senior Indebtedness then outstanding shall be paid in full, and (b) no claim or proof of claim shall be filed by or on behalf of Secured Party which shall assert any right to
receive any payments in respect of the principal of and interest 

  
 11.

 
due under the Notes or the Loans except subject to the payment in full of the principal of and interest on all of the Senior Indebtedness then outstanding. 

7.2        Default on Senior Indebtedness. If there shall occur an event
of default which has been declared in writing with respect to any Senior Indebtedness, as defined therein, or in the instrument under which it is outstanding, permitting the holder to accelerate the maturity thereof and Secured Party shall have
received written notice thereof from the holder of such Senior Indebtedness, then, unless and until such event of default shall have been cured or waived or shall have ceased to exist, or all Senior Indebtedness shall have been paid in full, no
payment shall be made in respect of the principal of or interest on the Notes or the Loans. 

7.3        Further Assurances. By acceptance of this Security Agreement,
Secured Party agrees to execute and deliver customary forms of subordination agreement requested from time to time by the holder of the Senior Indebtedness and, as a condition to Secured Party’s rights hereunder, Grantor may require that
Secured Party execute such forms of subordination agreement, provided that such forms shall not impose on Secured Party terms less favorable than those provided herein. 

7.4        Subrogation. Subject to the payment in full of all Senior
Indebtedness, Secured Party shall be subrogated to the rights of the holder of such Senior Indebtedness (to the extent of the payments or distributions made to the holder of such Senior Indebtedness pursuant to the provisions of this
Section 7) to receive payments and distributions of assets of Grantor applicable to the Senior Indebtedness. No such payments or distributions applicable to the Senior Indebtedness shall, as between Grantor and its creditors, other than
the holders of Senior Indebtedness and Secured Party, be deemed to be a payment by Grantor to or on account of the Notes or the Loans; and for purposes of such subrogation, no payments or distributions to the holders of Senior Indebtedness to which
Secured Party would be entitled except for the provisions of this Section 7 shall, as between Grantor and its creditors, other than the holders of Senior Indebtedness and Secured Party, be deemed to be a payment by Grantor to or on
account of the Senior Indebtedness. 
 7.5        No Impairment.
Subject to the rights, if any, of the holder of Senior Indebtedness under this Section 7 to receive cash, securities or other properties otherwise payable or deliverable to Secured Party, nothing contained in this Section 7
shall impair, as between Grantor and Secured Party, the obligation of Grantor, subject to the terms and conditions hereof, to pay to Secured Party the principal and interest under the Notes as and when the same become due and payable, or shall
prevent Secured Party, upon default hereunder, from exercising all rights, powers and remedies otherwise provided herein or by applicable law. 
 7.6        Lien Subordination. Any Lien or security interest of Secured Party, whether now or hereafter existing in connection with the amounts due under the
Notes or the Loans, on any assets or property of Grantor or any proceeds or revenues therefrom which Secured Party may have at any time as security for any amounts due and obligations under the Loans, including the Lien and security interest created
by this Security Agreement, shall be subordinate to all Liens or security interests now or hereafter granted to the holder of Senior Indebtedness by Grantor or by law notwithstanding the date, order or method of attachment or perfection of any such
Lien or security interest or the provisions of any applicable law. 

  
 12.

 7.7        Applicability of
Priorities. The priority of the holder of the Senior Indebtedness provided for herein with respect to security interests and Liens are applicable only to the extent that such security interests and Liens are enforceable and perfected and have
not been avoided; if a security interest or Lien is judicially determined to be unenforceable or unperfected or is judicially avoided with respect to any claim of the holder of the Senior Indebtedness or any part thereof, the priority provided for
herein shall not be available to such security interest or Lien to the extent that it is avoided or determined to be unenforceable or unperfected. The foregoing notwithstanding, Secured Party covenants and agrees that it shall not challenge, attack
or seek to avoid any security interest or Lien to the extent that it secures the holder of the Senior Indebtedness. Nothing in this Section 7.7 affects the operation of any subordination of indebtedness or turnover of payment provisions
hereof, or of any other agreements among any of the parties hereto. 

7.8        Reliance of Holders of Senior Indebtedness. Secured Party, by
its acceptance hereof, shall be deemed to acknowledge and agree that the foregoing subordination provisions are, and are intended to be, an inducement to and a consideration of the holder of Senior Indebtedness, whether such Senior Indebtedness was
created or acquired before or after the creation of the indebtedness evidenced by the Notes, and the holder of Senior Indebtedness shall be deemed conclusively to have relied on such subordination provisions in acquiring and holding, or in
continuing to hold, such Senior Indebtedness. 

8.        RIGHTS AND REMEDIES
UPON DEFAULT. Subject to the provisions of Section 7, beginning on the date which is ten (10) business days after any Event of Default shall have occurred and while such Event of Default is
continuing: 
 (a)        Secured Party may exercise in addition
to all other rights and remedies granted to it under this Security Agreement, the Notes, or the Purchase Agreement, all rights and remedies of a secured party under the UCC. Without limiting the generality of the foregoing, Grantor expressly agrees
that in any such event Secured Party, without demand of performance or other demand, advertisement or notice of any kind (except the notice specified below of time and place of public or private sale) to or upon Grantor or any other person, may
(i) reclaim, take possession, recover, store, maintain, finish, repair, prepare for sale or lease, shop, advertise for sale or lease and sell or lease (in the manner provided herein) the Collateral, and in connection with the liquidation of the
Collateral and collection of the accounts receivable pledged as Collateral, use any Trademark, Copyright, or process used or owned by Grantor and (ii) forthwith collect, receive, appropriate and realize upon the Collateral, or any part thereof,
and may forthwith sell, lease, assign, give an option or options to purchase or sell or otherwise dispose of and deliver said Collateral (or contract to do so), or any part thereof, in one or more parcels at public or private sale or sales, at any
exchange or broker’s board or at any of Secured Party’s offices or elsewhere at such prices as it may deem commercially reasonable, for cash or on credit or for future delivery without assumption of any credit risk. Grantor further agrees,
at Secured Party’s request, to assemble the Collateral and make it available to the Secured Party at places which Secured Party shall reasonably select, whether at Grantor’s premises or elsewhere. Secured Party shall apply the net proceeds
of any such collection, recovery, receipt, appropriation, realization or sale as provided in Section 8(e), below, with Grantor remaining liable for any deficiency remaining unpaid after such application. Grantor agrees that Secured Party
need not give more than twenty (20) days’ notice of the time and place of any public sale 

  
 13.

 
or of the time after which a private sale may take place and that such notice is reasonable notification of such matters. 

(b)        As to any Collateral constituting certificated securities or
uncertificated securities, if, at any time when Secured Party shall determine to exercise its right to sell the whole or any part of such Collateral hereunder, such Collateral or the part thereof to be sold shall not, for any reason whatsoever, be
effectively registered under Securities Act of 1933, as amended (as so amended the “Act”), Secured Party may, in its discretion (subject only to applicable requirements of law), sell such Collateral or part thereof by private
sale in such manner and under such circumstances as Secured Party may deem necessary or advisable, but subject to the other requirements of this Section 8(b), and shall not be required to effect such registration or cause the same to be
effected. Without limiting the generality of the foregoing, in any such event Secured Party may, in its sole discretion, (i) in accordance with applicable securities laws, proceed to make such private sale notwithstanding that a registration
statement for the purpose of registering such Collateral or part thereof could be or shall have been filed under the Act; (ii) approach and negotiate with a single possible purchaser to effect such sale; and (iii) restrict such sale
to a purchaser who will represent and agree that such purchaser is purchasing for its own account, for investment, and not with a view to the distribution or sale of such Collateral or part thereof. In addition to a private sale as
provided above in this Section 8(b), if any of such Collateral shall not be freely distributable to the public without registration under the Act at the time of any proposed sale hereunder, then Secured Party shall not be required to
effect such registration or cause the same to be effected but may, in its sole discretion (subject only to applicable requirements of law), require that any sale hereunder (including a sale at auction) be conducted subject to such restrictions
as Secured Party may, in its sole discretion, deem necessary or appropriate in order that such sale (notwithstanding any failure so to register) may be effected in compliance with the Bankruptcy Code and other laws affecting the enforcement of
creditors’ rights and the Act and all applicable state securities laws. 

(c)        Grantor also agrees to pay all fees, costs and expenses of
Secured Party, including, without limitation, attorneys’ fees, incurred in connection with the enforcement of any of its rights and remedies hereunder. 
 (d)        Grantor hereby waives presentment, demand, protest or any notice (to the maximum extent permitted by applicable law) of any kind in connection
with this Security Agreement or any Collateral. 

(e)        Subject to the provisions of Section 7, the
Proceeds of any sale, disposition or other realization upon all or any part of the Collateral shall be distributed by Secured Party in the following order of priorities: 

FIRST, to Secured Party in an amount sufficient to pay in full the costs of Secured
Party in connection with such sale, disposition or other realization, including all fees, costs, expenses, liabilities and advances incurred or made by Secured Party in connection therewith, including, without limitation, attorneys’ fees;

 SECOND, to Secured Party in an amount equal to the then unpaid Secured
Obligations; and 

  
 14.

     FINALLY, upon
payment in full of the Secured Obligations, to Grantor or its representatives, in accordance with the UCC or as a court of competent jurisdiction may direct. 
 9.        INDEMNITY. Grantor agrees to defend, indemnify and hold harmless Secured Party and its officers, employees, and
agents against (a) all obligations, demands, claims, and liabilities claimed or asserted by any other party in connection with the transactions contemplated by this Security Agreement and (b) all losses or expenses in any way suffered,
incurred, or paid by Secured Party as a result of or in any way arising out of, following or consequential to transactions between Secured Party and Grantor, whether under this Security Agreement or otherwise (including without limitation,
reasonable attorneys fees and expenses), except for losses arising from or out of Secured Party’s gross negligence or willful misconduct. 
 10.        REINSTATEMENT. This Security Agreement shall remain in full force and effect and continue to be effective should any
petition be filed by or against Grantor for liquidation or reorganization, should Grantor become insolvent or make an assignment for the benefit of creditors or should a receiver or trustee be appointed for all or any significant part of
Grantor’s property and assets, and shall continue to be effective or be reinstated, as the case may be, if at any time payment and performance of the Secured Obligations, or any part thereof, is, pursuant to applicable law, rescinded or reduced
in amount, or must otherwise be restored or returned by any obligee of the Secured Obligations, whether as a “voidable preference,” “fraudulent conveyance,” or otherwise, all as though such payment or performance had not been
made. In the event that any payment, or any part thereof, is rescinded, reduced, restored or returned, the Secured Obligations shall be reinstated and deemed reduced only by such amount paid and not so rescinded, reduced, restored or returned.

 11.        MISCELLANEOUS. 

    11.1        Waivers; Amendments. Any
amendment of the Notes, the Purchase Agreement or this Security Agreement shall require the written consent of the Grantor and each Secured Party. 
     11.2        Termination of this Security Agreement. Subject to Section 10 hereof, this
Security Agreement shall terminate upon the payment and performance in full of the Secured Obligations. 

    11.3        Successor and Assigns. This Security
Agreement and all obligations of Grantor hereunder shall be binding upon the successors and assigns of Grantor, and shall, together with the rights and remedies of Secured Party hereunder, inure to the benefit of Secured Party, any future holder of
any of the Secured Obligations and their respective successors and assigns. No sales of participations, other sales, assignments, transfers or other dispositions of any agreement governing or instrument evidencing the Secured Obligations or any
portion thereof or interest therein shall in any manner affect the lien granted to Secured Party hereunder. 

    11.4        Governing Law. In all respects,
including all matters of construction, validity and performance, this Security Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of California applicable to contracts made and performed in such
state, without regard to the principles thereof regarding conflict of laws, 

  
 15.

 
except to the extent that the UCC provides for the application of the law of a different jurisdiction. 

  
 16.

 IN WITNESS
WHEREOF, each of the parties hereto has caused this Security Agreement to be executed and delivered by its duly authorized officer on the date first set forth above. 

 

									
	 ADDRESS OF GRANTOR
	  		  	 BIOCEPT, INC., as Grantor

			
	 5810 Nancy Ridge Dr.
	  		  	
By:                             
                                         
         

			
	 San Diego, CA 92121
	  		  	
Printed Name:                          
                                   

				
		  		  		  	
Title:                            
                                         
       

			
	 TAXPAYER IDENTIFICATION NUMBER
OF
GRANTOR
	  		  	 JURISDICTION OF ORGANIZATION
OF
GRANTOR

			
	  
	  		  	 California

				
	 ACCEPTED AND ACKNOWLEDGED BY:
	  		  		  	
				
	 THE REISS FAMILY GST EXEMPT MARITAL
DEDUCTION
TRUST, as Secured Party
	  		  		  	
				
	
By:                             
                                         
         
	  		  		  	
				
	 Printed
Name:                                        
                     
	  		  		  	
				
	
Title:                            
                                         
       
	  		  		  	
				
	 THE REISS FAMILY SURVIVOR’S TRUST
UDT
DATED DECEMBER 19, 1988, as Secured Party
	  		  		  	
				
	
By:                             
                                         
         
	  		  		  	
				
	
Printed Name:                          
                                   
	  		  		  	
				
	
Title:                            
                                         
       
	  		  		  	

 [SIGNATURE PAGE TO SECURITY
AGREEMENT] 

 SCHEDULE A 

LIENS EXISTING ON THE DATE OF THIS SECURITY AGREEMENT 
 1. The Reiss Family GST Exempt Marital Deduction Trust was granted a security interest on the assets of the Grantor pursuant to the terms of that certain Security Agreement dated December 22, 2008.

 2. Goodman Co. Ltd. was granted a security interest on the assets of the Grantor pursuant to the terms of that certain
Subordinated Security Agreement. 
 3. Ervin Leasing Company has been granted a security interest on certain assets of the
Grantor. This security interest relates to a capital lease which terminates in February of 2011, following which the Company will own the underlying equipment and the security interest will be released. 

4. TCF Equipment Finance, Inc. has been granted a security interest on certain assets of the Grantor. This security interest relates to a
capital lease which terminates in March of 2011, following which the Company will own the underlying equipment and the security interest will be released. 
 5. Key Equipment Finance Inc. has been granted a security interest on certain assets of the Grantor. 

 SCHEDULE B 

LOCATION OF GOODS 
  

			
	 ENTITY
	  	 ADDRESS

	Biocept, Inc.	  	 5810 Nancy Ridge Dr., San Diego, CA 92121

		
	Custom Engineering Plastics (tooling)	  	 8558 Miramar Place, San Diego, CA 92121

 SCHEDULE C 

LIST OF CHATTEL PAPER, INSTRUMENTS, AND 
 INVESTMENT PROPERTY 
 (CERTIFICATED SECURITIES) 

None 

 SCHEDULE D 

DEPOSIT ACCOUNTS, SECURITIES ACCOUNTS AND 
 COMMODITY ACCOUNTS 
 (Including Type of Account, Account Name, Account
Number and Name and Address of Institution/Intermediary) 
  

							
	 DESCRIPTION
	  	 TYPE OF ACCOUNT
	  	 ACCOUNT NAME
	  	 ACCOUNT NUMBER

	 CALIFORNIA COAST CREDIT UNION SAVINGS
	  	 SAVINGS
	  	 BIOCEPT, INC.
	  	 7100001171

	 PO BOX 502080
	  		  		  	
	 SAN DIEGO, CA 92150
	  		  		  	
				
	 SILICON VALLEY BANK
	  	 ANALYSIS CHECKING
	  	 BIOCEPT, INC.
	  	 3300575742

	 3003 TASMAN DRIVE
	  		  		  	
	 SANTA CLARA, CA 95054
	  		  		  	
				
	 SILICON VALLEY BANK
	  	 MONEY MARKET ACCOUNT
	  	 BIOCEPT, INC.
	  	 3300668920

	 3003 TASMAN DRIVE
	  		  		  	
	 SANTA CLARA, CA 95054
	  		  		  	
				
	 SILICON VALLEY BANK
	  	 FLEX ANALYSIS CHECKING
	  	 BIOCEPT, INC.
	  	 3300698833

	 3003 TASMAN DRIVE
	  		  		  	
	 SANTA CLARA, CA 95054
	  		  		  	

 SCHEDULE E 

INTELLECTUAL PROPERTY 
  

																	
	 Docket No.
	  	 Title
	  	 Inventors
	  	 Appln. No.
	  	 Filing Date
	  	 Patent No.
	  	 Issue Date
	  	 Status
	  	Comments
	BIO-001 FAMILY
									
	 BIOE-001/00US
	  	 RECOVERY OF
RARE CELLS USING A
MICROCHANNEL
APPARATUS WITH
PATTERNED POSTS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	11/038,920	  	Jan-18-2005	  		  		  	Notice of Withdrawal from Issue (Oct-12-2010); Office Action issued
Dec-09-2010	  	Pending
									
	 BIOE-001/01US
	  	 RECOVERY OF
RARE CELLS
USING
A MICROCHANNEL
APPARATUS WITH
PATTERNED POSTS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	11/458,668	  	Jul-19-2006	  		  		  	 On Appeal—
 Reply Brief filed Feb-01-2010
	  	 Pending

									
	 BIOE-001/01WO
	  	 DETECTION OR
ISOLATION OF
TARGET MOLECULES
USING A
MICROCHANNEL
APPARATUS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	PCT/US2007/073817	  	Jul-18-2007	  		  		  	 EXPIRED/PCT OVER
 National Phase
	  	Expired/PCT
Period
Over
									
	 BIOE-001/01CA
	  	 DETECTION OR
ISOLATION OF
TARGET
MOLECULES USING A
 MICROCHANNEL APPARATUS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	2,658,336	  	Jul-18-2007	  		  		  	Application Filed	  	Pending

  
 1 

																	
	 Docket No.
	  	 Title
	  	 Inventors
	  	 Appln. No.
	  	 Filing Date
	  	 Patent No.
	  	 Issue Date
	  	 Status
	  	Comments
	 BIOE-001/01JP
	  	 DETECTION OR
ISOLATION OF
TARGET
MOLECULES USING
A MICROCHANNEL
APPARATUS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	2009-520982	  	Jul-18-2007	  		  		  	 Exam
 Requested
	  	Pending
									
	 BIOE-001/01CN
	  	 DETECTION OR
ISOLATION OF
TARGET
MOLECULES USING
A MICROCHANNEL
APPARATUS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	200780032530.2	  	Jul-18-2007	  		  		  	Published (Application Extended to HK)	  	Pending
									
	 BIOE-001/01KR
	  	 DETECTION OR
ISOLATION OF
TARGET
MOLECULES USING
A MICROCHANNEL
APPARATUS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	10-2009-7003339	  	Jul-18-2007	  		  		  	 Application
 Filed
	  	Pending
									
	 BIOE-001/01IN
	  	 DETECTION OR
ISOLATION OF
TARGET
MOLECULES USING
A MICROCHANNEL
APPARATUS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	269/KOLNP/2009	  	Jul-18-2007	  		  		  	 Exam
 Requested
	  	Pending
									
	 BIOE-001/01IL
	  	 DETECTION OR
ISOLATION OF
TARGET
MOLECULES USING
A MICROCHANNEL
APPARATUS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	196553	  	Jul-18-2007	  		  		  	Application Filed	  	Pending

  
 2 

																	
	 Docket No.
	  	 Title
	  	 Inventors
	  	 Appln. No.
	  	 Filing Date
	  	 Patent No.
	  	 Issue Date
	  	 Status
	  	Comments
	 BIOE-001/01EP
	  	 DETECTION OR
ISOLATION OF
TARGET
MOLECULES
USING A
MICROCHANNEL
APPARATUS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	07813079.6	  	Jul-18-2007	  		  		  	Published (Claims amended in response to EP Search Report Apr-16-2009)	  	Pending
									
	 BIOE-001/01HK
	  	 DETECTION OR
ISOLATION OF
TARGET
MOLECULES
USING A
MICROCHANNEL
APPARATUS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	09105117.8	  	Jul-18-2007	  		  		  	 Application
 Filed
	  	Pending
									
	 BIOE-001/02US
	  	 RECOVERY OF
RARE CELLS
USING A
MICROCHANNEL
APPARATUS
WITH
PATTTERNED
POSTS
	  	 Zhongliang
 TANG; Pavel
 TSINBERG
	  	60/678,004	  	May-04-2005	  		  		  	 Expired
 Provisional
 Application

(May-04-2006)
	  	Expired
Provisional
									
	 BIOE-001/03WO
	  	 CELL
SEPARATION
USING
MICROCHANNEL
HAVING
PATTERNED
POSTS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	PCT/US2006/000383	  	Jan-05-2006	  		  		  	EXPIRED/PCT OVER National Phase	  	Expired/PCT
Period
Over
									
	 BIOE-001/03TW
	  	 CELL
SEPARATION
USING
MICROCHANNEL
HAVING
PATTERNED
POSTS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	95115566	  	Jan-05-2006	  		  		  	 Exam
 Requested
	  	Pending

  
 3 

																	
	 Docket No.
	  	 Title
	  	 Inventors
	  	 Appln. No.
	  	 Filing Date
	  	 Patent No.
	  	 Issue Date
	  	 Status
	  	Comments
	 BIOE-001/03CN
	  	 CELL SEPARATION
USING
MICROCHANNEL
HAVING
PATTERNED POSTS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	200680002401.4	  	Jan-05-2006	  		  		  	Response Filed	  	Pending
									
	 BIOE-001/03EP
	  	 CELL SEPARATION
USING
MICROCHANNEL
HAVING
PATTERNED POSTS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	06717562.0	  	Jan-05-2006	  		  		  	Published (Claims amended in response to EP Search Report Aug-07-2007); Office Action issued regarding formality issues (Nov-26-2010)	  	Pending
									
	 BIOE-001/03IL
	  	 CELL SEPARATION
USING MICROCHANNEL
HAVING
PATTERNED POSTS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	184345	  	Jan-05-2006	  		  		  	Office Action Issued Regarding disclose of references—duty to disclose references in progress	  	Pending
									
	 BIOE-001/03IN
	  	 CELL SEPARATION
USING
MICROCHANNEL
HAVING
PATTERNED POSTS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	2991/KOLNP/2007	  	Jan-05-2006	  		  		  	Exam Requested	  	Pending

  
 4 

																	
	 Docket No.
	  	 Title
	  	 Inventors
	  	 Appln. No.
	  	 Filing Date
	  	 Patent No.
	  	 Issue Date
	  	 Status
	  	Comments
	 BIOE-001/03JP
	  	 CELL

 SEPARATION

 USING

MICROCHANNEL    

 HAVING

 PATTERNED

POSTS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	2007-551296	  	Jan-05-2006	  		  		  	 Exam
 Requested
	  	Pending
									
	 BIOE-001/03KR
	  	 CELL

 SEPARATION

 USING

MICROCHANNEL

HAVING

PATTERNED POSTS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	10-2007-7018895	  	Jan-05-2006	  		  		  	 Exam
 Requested
	  	Pending
									
	 BIOE-001/03US
	  	 CELL

 SEPARATION

 USING

MICROCHANNEL

HAVING

PATTERNED

POSTS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	11/814,276	  	Jan-05-2006	  		  		  	 Office Action
 received Sept-
 09-2010
	  	Pending
									
	 BIOE-001/03HK
	  	 CELL

 SEPARATION

 USING

MICROCHANNEL

HAVING

PATTERNED

POSTS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	08107280.6	  	Jan-05-2006	  		  		  	Published	  	Pending
									
	 BIOE-001/04HK
	  	 DETECTION OR

 ISOLATION OF

 TARGET

MOLECULES

USING A

MICROCHANNEL

APPARATUS
	  	 Zhongliang
 TANG; Ram
 BHATT; Pavel

TSINBERG
	  	10102459.8	  	Jul-18-2007	  		  		  	Published	  	Pending

  
 5 

																	
	 Docket No.
	  	 Title
	  	 Inventors
	  	 Appln. No.
	  	 Filing Date
	  	 Patent No.
	  	 Issue Date
	  	 Status
	  	Comments
	BIOE-002 FAMILY
									
	 BIOE-002/00US
	  	 BEADS FOR

 CAPTURING

 TARGET CELLS

FROM BODILY

 FLUID
	  	 David NAFF;
 Zhongliang
 TANG; Pavel

TSINBERG
	  	11/021,304	  	Dec-23-2004	  	7,439,062	  	Oct-21-2008	  	Issued	  	Issued
									
	 BIOE-002/00WO
	  	 ISOLATION OF

 CELLS OR THE LIKE
FROM

 BODILY

FLUIDS
	  	 Ram BHATT;
 Pavel
 TSINBERG
	  	PCT/US2005/046961	  	Dec-21-2005	  		  		  	 EXPIRED/PCT OVER
 National Phase
	  	Expired/PCT
Period
Over
	
	 BIOE-005 FAMILY

									
	 BIOE-005/00US
	  	 DEVICE FOR CELL
SEPARATION AND
ANALYSIS AND
METHOD OF
USING
	  	 Zhongliang
 TANG; Pavel
 TSINBERG
	  	11/331,988	  	Jan-12-2006	  	7,695,9456	  	Apr-3-2010	  	Issued	  	Issued
									
	 BIOE-005/01CN
	  	 DETECTION, SEPARATION OR
ISOLATION
OF TARGET
MOLECULES USING
A MICROCHANNEL
APPARATUS
	  	 Pavel
 TSINBERG ;
 Zhongliang

TANG
	  	20078003143.6	  	Jan-12-2007	  		  		  	 Exam
 Requested
 (Extended to

HK Aug-04-

2009)
	  	Pending
									
	 BIOE-005/01EP
	  	 DETECTION,
SEPARATION OR
ISOLATION OF
TARGET
MOLECULES USING
A MICROCHANNEL
APPARATUS
	  	 Pavel
 TSINBERG ;
 Zhongliang

TANG
	  	07717726.9	  	Jan-12-2007	  		  		  	 Published
 (Claims
 amended in

response to
 EP
Search
 Report Sep-
 29-2008)
	  	Pending

  
 6 

																	
	 Docket No.
	  	 Title
	  	 Inventors
	  	 Appln. No.
	  	 Filing Date
	  	 Patent No.
	  	 Issue Date
	  	 Status
	  	Comments
	 BIOE-005/01HK
	  	 DETECTION,
SEPARATION OR
ISOLATION OF
TARGET
MOLECULES USING
A MICROCHANNEL
APPARATUS
	  	 Pavel
 TSINBERG ;
 Zhongliang

TANG
	  	09102561.6	  	Jan-12-2007	  		  		  	Pending	  	Pending
									
	 BIOE-005/01IN
	  	 DETECTION,
SEPARATION OR
ISOLATION OF
TARGET
MOLECULES USING
A MICROCHANNEL
APPARATUS
	  	 Pavel
 TSINBERG ;
 Zhongliang

TANG
	  	2899/KOLNP/2008	  	Jan-12-2007	  		  		  	Exam Requested	  	Pending
									
	 BIOE-005/01JP
	  	 DETECTION,
SEPARATION OR
ISOLATION OF
TARGET MOLECULES
USING A
MICROCHANNEL
APPARATUS
	  	 Pavel
 TSINBERG ;
 Zhongliang

TANG
	  	2008-550541	  	Jan-12-2007	  		  		  	 Exam
 Requested
 (Divisional

Filed Mar-07-

2010)
	  	Pending
									
	 BIOE-005/01KR
	  	 DETECTION, SEPARATION
OR ISOLATION
OF TARGET
MOLECULES USING
A MICROCHANNEL
APPARATUS
	  	 Pavel
 TSINBERG ;
 Zhongliang

TANG
	  	10-2008-7019406	  	Jan-12-2007	  		  		  	Pending	  	Pending
									
	 BIOE-005/01US
	  	 DEVICE
FOR CELL
SEPARATION AND
ANALYSIS
AND METHOD
OF USING
	  	 Pavel
 TSINBERG ;
 Zhongliang

TANG
	  	12/721,510	  	Mar-10-2010	  		  		  	Published	  	Pending

  
 7 

																	
	 Docket No.
	  	 Title
	  	 Inventors
	  	 Appln. No.
	  	 Filing Date
	  	 Patent No.
	  	 Issue Date
	  	 Status
	  	Comments
	 BIOE-005/01WO
	  	 DETECTION,
SEPARATION
OR ISOLATION
OF TARGET
MOLECULES USING A MICROCHANNEL APPARATUS
	  	Pavel TSINBERG ; Zhongliang TANG	  	PCT/US2007/060518	  	Jan-12-2007	  		  		  	 EXPIRED/PCT OVER
 National Phase
	  	Expired/PCT
Period
Over
									
	 BIOE-005/02HK
	  	 DETECTION,
SEPARATION OR
ISOLATION
OF TARGET
MOLECULES USING A MICROCHANNEL
APPARATUS
	  	Pavel TSINBERG ; Zhongliang TANG	  	09107243.1	  	Jan-12-2007	  		  		  	Published	  	Pending
									
	 BIOE-005/02JP
	  	 DETECTION, SEPARATION OR
ISOLATION OF
TARGET MOLECULES USING A MICROCHANNEL APPARATUS
	  	 Pavel TSINBERG ; Zhongliang TANG

	  	2010-058590	  	Jan-12-2007	  		  		  	Published	  	Pending
	
	BIOE-008 FAMILY
									
	 BIOE-008/00US
	  	 ENRICHMENT OF
FETAL DNA FROM CERVICAL
MUCUS
	  		  	N/A	  	N/A	  	N/A	  	N/A	  	Never Filed	  	Never
Filed
	
	BIOE-010 FAMILY
									
	 BIOE-010/00US
	  	 NON-INVASIVE DETECTION OF
ENDOMETRIAL CANCER
	  		  	60/915,554	  	May-02-2007	  		  		  	Expired	  	Expired
Provisional
									
	 BIOE-010/01US
	  	 NON-INVASIVE
DETECTION OF
ENDOMETRIAL
CANCER
	  	Quynh H. LE; Herbert RADISCH	  	12/114,584	  	May-02-2008	  		  		  	Abandoned	  	Abandoned

  
 8 

																	
	 Docket No.
	  	 Title
	  	 Inventors
	  	 Appln. No.
	  	 Filing Date
	  	 Patent No.
	  	 Issue Date
	  	 Status
	  	Comments
	 BIOE-010/01WO
	  	 NON-INVASIVE DETECTION OF
ENDOMETRIAL
CANCER
	  	Quynh H. LE; Herbert RADISCH	  	PCT/US2008/062286	  	May-01-2008	  		  		  	Abandoned	  	Abandoned
	
	BIOE-011 FAMILY
									
	 BIOE-011/00US
	  	 CELL SEPARATION USING
DOUBLE-SLIDE
ARRANGEMENT
	  		  	N/A	  	N/A	  	N/A	  	N/A	  	Never Filed	  	Never
Filed
	
	BIOE-012 FAMILY
									
	 BIOE-012/00US
	  	 COLLECTION, SEPARATION, PURIFICATION AND TESTING OF
TROPHOBLASTS
	  		  	N/A	  	N/A	  	N/A	  	N/A	  	Never Filed	  	Never
Filed
	
	BIOE-019 FAMILY
									
	 BIOE-019/00US
	  	 ISOLATION OF
FETAL
DNA FROM
MATERNAL BLOOD
	  	Fan WEN-HUA; Irene POSTOR; Tim ROGER; Ram BHATT	  	N/A	  	N/A	  	N/A	  	N/A	  	Never Filed	  	Never
Filed
	
	BIOE-020 FAMILY
									
	 BIOE-020/00US
	  	 ALTERNATE METHODS OF
CELL CAPTURE
ON THE
MEMS CHANNEL
	  	Steve MIKOLAJCZYK; Tony PIRCHER; Pavel TSINBERG	  	61/163,009	  	Mar-24-2009	  		  		  	Expired	  	Expired
Provisional
									
	 BIOE-020/01US
	  	 ALTERNATE METHODS
OF CELL
CAPTURE ON
THE
MEMS CHANNEL
	  	Steve MIKOLAJCZYK; Tony PIRCHER; Pavel T
SINBERG	  	61/235,615	  	Aug-20-2009	  		  		  	Expired	  	Expired
Provisional

  
 9 

																	
	 Docket No.
	  	 Title
	  	 Inventors
	  	 Appln. No.
	  	 Filing Date
	  	 Patent No.
	  	 Issue Date
	  	 Status
	  	Comments
	 BIOE-020/02US
	  	 DEVICES
AND METHODS OF CELL
CAPTURE AND ANALYSIS
	  	Steve MIKOLAJCZYK; Tony PIRCHER; Pavel TSINBERG; Farideh Z. BISCHOFF	  	12/730,738	  	Mar-24-2010	  		  		  	Published	  	Claims
priority
to US
61/298,871;
US
61/235,615
and US
61/163,009
									
	 BIOE-020/02WO
	  	 DEVICES
AND METHODS OF CELL
CAPTURE AND ANALYSIS
	  	Steve MIKOLAJCZYK; Tony PIRCHER; Pavel TSINBERG; Farideh Z. BISCHOFF	  	PCT/US2010/028499	  	Mar-24-2010	  		  		  	 Published
 (National Phase Due: Sep-24-2011)
	  	Claims
priority
to US
61/298,871;
US
61/235,615
and US
61/163,009
	
	BIOE-022 FAMILY
									
	 BIOE-022/00US
	  	 CIRCULATING
TUMOR CELL CAPTURE
IN A MICROFLOW APPARATUS
	  	Farideh Z. BISCHOFF	  	61/298,871	  	Jan-27-2010	  		  		  	Provisional	  	Due to
expire:
Jan-27-
2011
(to be
incorporated
with
BIOE-
020 as
CIP)
	
	BIOE-023 FAMILY
									
	 BIOE-023/00US
	  	 CELL COLLECTION
TRAP FOR
MICROFLUIDIC
DEVICES

	  	Pavel TSINBERG; Timothy WILSON; Tony PIRCHER; Karena KOSCO	  	61/329,307	  	Apr-29-2010	  		  		  	Provisional	  	Due to
expire:
Apr-29-
2011
	
	BIOE-024 FAMILY
									
	 BIOE-024/00US
	  	 ANEUPLOIDY COMPLEXITY
	  		  	61/385,936	  	Sep-23-2010	  		  		  	Provisional	  	Due to
expire:
Sep-23-
2011
									
	 BIOE-024/01US
	  	 ANEUPLOIDY COMPLEXITY
	  		  	61/386,426	  	Sep-24-2010	  		  		  	Provisional	  	Due to
expire:
Sep-24-
2011

  
 10 

																	
	 Docket No.
	  	 Title
	  	 Inventors
	  	 Appln. No.
	  	 Filing Date
	  	 Patent No.
	  	 Issue Date
	  	 Status
	  	Comments
	
	BIOE-025 FAMILY
									
	 BIOE-025/00US
	  	 USE OF
DIAZOLIDINYL
UREA FOR
ANTI-CLUMPING OF
BIOLOGICAL SAMPLE
	  		  	61/385,935	  	Sep-23-2010	  		  		  	Provisional	  	Due to
expire:
Sep-23-
2011
	
	BIOE-026 FAMILY
									
	 BIOE-026/00US
	  	 SIGNAL AMPLIFICATION
	  	Steve MIKOLAJCZYK	  	61/385,937	  	Sep-23-2010	  		  		  	Provisional	  	Due to
expire:
Sep-23-
2011
	
	BIOE-027 FAMILY
									
	 BIOE-027/00US
	  	 DIAGNOSTIC AND
PROGNOSTIC USES OF
SIGNAL AMPLIFICATION
	  	Farideh Z. BISCHOFF	  	61/431,385	  	Jan-10-2011	  		  		  	Provisional	  	Due to
expire:
Jan-10-
2012

  

											
	 Docket No.        
	  	
            Country         
   
	  	 Title
	  	 Application No./

Filing Date
	  	 Patent No./

Issue Date
	  	 Status

	 6776-62685
	  	 S. Korea
	  	 METHOD OF USING AN IMPROVED PEPTIDE
NUCLEIC ACID UNIVERSAL LIBRARY TO
OPTIMIZE DNA SEQUENCE HYBRIDIZATION
	  	 7000159/2001
 July 1, 1999
	  	 694914
 March 7, 2007
	  	 Issued

						
	 6776-62829
	  	 United States of
America
	  	 METHOD OF MAKING BIOCHIPS AND THE
BIOCHIPS RESULTING THEREFROM
	  	 09/299,831
 April 26, 1999
	  	 6,174,683
 January 16, 2001
	  	 Issued

						
	 6776-66152
	  	 United States of
America
	  	 PEPTIDE NUCLEIC ACID PRECURSORS AND
METHODS OF PREPARING SAME
	  	 09/479,320
 January 5, 2000
	  	 6,433,134
 August 13, 2002
	  	 Issued

						
	 6776-66233
	  	 S. Korea
	  	 METHOD OF MAKING BIOCHIPS AND THE
BIOCHIPS RESULTING THEREFROM
	  	 7013634/2001
 April 26, 2000
	  	 109795
 April 13, 2007
	  	 Issued

						
	 6776-71716
	  	 France
	  	 MICROWELL BIOCHIP
	  	 02778545.0
 October 15,
2002
	  	 1444500
 June 11, 2008
	  	 Issued

						
	 6776-71716
	  	 Germany
	  	 MICROWELL BIOCHIP
	  	 02778545.0
 October 15,
2002
	  	 60227094.4-08
 June 11, 2008
	  	 Issued

						
	 6776-71716
	  	 United Kingdom
	  	 MICROWELL BIOCHIP
	  	 02778545.0
 October 15,
2002
	  	 1444500
 June 11, 2008
	  	 Issued

  
 11 

											
	 Docket No.        
	  	
            Country         
   
	  	 Title
	  	 Application No./

Filing Date
	  	 Patent No./

Issue Date
	  	 Status

	 6776-71716
	  	 Japan
	  	 MICROWELL BIOCHIP
	  	 2003-536713
 October 15, 2002
	  	 4,117,249
 April 25, 2008
	  	 Issued

						
	 6776-71726
	  	 United States of
America
	  	 THREE DIMENSIONAL FORMAL BIOCHIPS
	  	 10/054,728
 October 25, 2001
	  	 7,638,464
 December 29, 2009
	  	 Issued

						
	 6776-72711
	  	 Israel
	  	 METHODS AND GEL COMPOSITIONS FOR
ENCAPSULATING LIVING CELLS AND
ORGANIC MOLECULES
	  	 158128
 April 2, 2002
	  	 158128
 December 24, 2009
	  	 Issued

						
	 6776-72711
	  	 Japan
	  	 METHODS AND GEL COMPOSITIONS FOR
ENCAPSULATING LIVING CELLS AND
ORGANIC MOLECULES
	  	 2002-580026
 April 2, 2002
	  	 4,198,468
 October 10, 2008
	  	 Issued

						
	 6776-72711
	  	 United States of
America
	  	 METHODS AND GEL COMPOSITIONS FOR
ENCAPSULATING LIVING CELLS AND
ORGANIC MOLECULES
	  	 10/398,725
 April 2, 2003
	  	 7,172,866
 February 6, 2007
	  	 Issued

						
	 6776-81634
	  	 United States of
America
	  	 REFLECTIVE SUBSTRATE AND ALGORITHMS
FOR 3D BIOCHIP
	  	 10/664,248
 September 16, 2003
	  	 7,198,901
 April 3, 2007
	  	 Issued

						
	 6776-81673
	  	 United States of
America
	  	 MICROARRAYS UTILIZING HYDROGELS
	  	 10/922,391
 August 19, 2004
	  	 7,595,157
 September 29, 2009
	  	 Issued

						
	 6776-81721
	  	 United States of
America
	  	 MICROWELL BIOCHIP
	  	 10/823,021
 April 12, 2004
	  	 7,217,520
 May 15, 2007
	  	 Issued

  
 12 

 TRADEMARKS 

 

															
	 Mark
	  	 Country
	  	Application
No.	  	Application
Date	  	Registration
No.	  	Registration
Date	  	Status	  	International Classes
	 3D
 HYDROARRAY
	  	 United States of America
	  	 78/299,957
	  	 Sep-12-2003
	  	 3,000,775
	  	 Sep-27-2005
	  	 Registered
	  	 01,  09

								
	 BIOCEPT
	  	 United States of America
	  	 78/116,876
	  	 Mar-22-2002
	  	 2,880,222
	  	 Aug-31-2004
	  	 Registered
	  	 09

								
	 BIOCEPT
 LABORATORIES
	  	 United States of America
	  	 78/412,723
	  	 May-04-2004
	  	 3,159,956
	  	 Oct-17-2006
	  	 Registered
	  	 09,  42

								
	 CEE
	  	 United States of America
	  	 78/648,645
	  	 Jun-10-2005
	  	 3,326,287
	  	 Oct-30-2007
	  	 Registered
	  	 44

								
	 CEE-ENHANCED
	  	 United States of America
	  	 85/121,217
	  	 Sep-01-2010
	  		  		  	 Pending
	  	 05

								
	 CEE-SURE
	  	 United States of America
	  	 85/121,215
	  	 Sep-01-2010
	  		  		  	 Pending
	  	 05

								
	 CHIPCALC
	  	 United States of America
	  	 78/341,146
	  	 Dec-15-2003
	  	 2,999,101
	  	 Sep-20-2005
	  	 Registered
	  	 09

								
	 ENGINEERING NEW DIRECTIONS IN DIAGNOSTICS
	  	 United States of America
	  	 77/102,753
	  	 Feb-08-2007
	  	 3,458,860
	  	 Jul-01-2008
	  	 Registered
	  	 44

								
	 HYDROARRAY
	  	 United States of America
	  	 78/282,032
	  	 Aug-01-2003
	  	 2,934,749
	  	 Mar-22-2005
	  	 Registered
	  	 01,  09

								
	 ONCOCEE
	  	 United States of America
	  	 77/768,632
	  	 Jun-25-2009
	  		  		  	 Allowed
	  	 05,  09,  10,  42,  44

								
	 ONCOCEE-BL
	  	 United States of America
	  	 85/115,130
	  	 Aug-24-2010
	  		  		  	 Pending
	  	 05

								
	 ONCOCEE-BN
	  	 United States of America
	  	 85/132,281
	  	 Sep-17-2010
	  		  		  	 Pending
	  	 05

								
	 ONCOCEE-BR
	  	 United States of America
	  	 85/115,123
	  	 Aug-24-2010
	  		  		  	 Pending
	  	 05

								
	 ONCOCEE-CE
	  	 United States of America
	  	 85/115,995
	  	 Aug-25-2010
	  		  		  	 Pending
	  	 05

								
	 ONCOCEE-CR
	  	 United States of America
	  	 85/115,126
	  	 Aug-24-2010
	  		  		  	 Pending
	  	 05

								
	 ONCOCEE-GI
	  	 United States of America
	  	 85/116,005
	  	 Aug-25-2010
	  		  		  	 Pending
	  	 05

								
	 ONCOCEE-LI
	  	 United States of America
	  	 85/116,002
	  	 Aug-25-2010
	  		  		  	 Pending
	  	 05

								
	 ONCOCEE-LU
	  	 United States of America
	  	 85/115,124
	  	 Aug-24-2010
	  		  		  	 Pending
	  	 05

								
	 ONCOCEE-ME
	  	 United States of America
	  	 85/116,000
	  	 Aug-25-2010
	  		  		  	 Pending
	  	 05

								
	 ONCOCEE-OV
	  	 United States of America
	  	 85/115,998
	  	 Aug-25-2010
	  		  		  	 Pending
	  	 05

								
	 ONCOCEE-PA
	  	 United States of America
	  	 85/115,127
	  	 Aug-24-2010
	  		  		  	 Pending
	  	 05

								
	 ONCOCEE-PR
	  	 United States of America
	  	 85/115,125
	  	 Aug-24-2010
	  		  		  	 Pending
	  	 05

								
	 ONCOCEE-RE
	  	 United States of America
	  	 85/116,001
	  	 Aug-25-2010
	  		  		  	 Pending
	  	 05

								
	 ONCOCEE-TE
	  	 United States of America
	  	 85/116,004
	  	 Aug-25-2010
	  		  		  	 Pending
	  	 05

								
	 ONCOCEE-UT
	  	 United States of America
	  	 85/115,131
	  	 Aug-24-2010
	  		  		  	 Pending
	  	 05

  
 13 

															
	 Mark
	  	 Country
	  	Application
No.	  	Application
Date	  	Registration
No.	  	Registration
Date	  	Status	  	International Classes
	 PERSONALIZED CANCER DIAGNOSTICS, ONE CELL AT A TIME
	  	 United States of America
	  	 85/115,120
	  	 Aug-24-2010
	  		  		  	 Pending
	  	 44

								
	 FIRSTCEE
	  	 European Community
	  	 6282719
	  	 Sep-17-2007
	  	 6282719
	  	 Sep-25-2008
	  	 Registered
	  	 01,  05,  09,  42,  44

								
	 PRECEED
	  	 European Community
	  	 4724101
	  	 Nov-16-2005
	  		  	 Nov-16-2006
	  	 Registered
	  	 09,  42

								
	 CEE
	  	 Japan
	  	 2007-2921
	  	 Jan-17-2007
	  	 5229880
	  	 May-15-2009
	  	 Registered
	  	 01,  05,  09,  10

								
	 CEE
	  	 Japan
	  	 2005-106515
	  	 Nov-11-2005
	  	 5229879
	  	 May-15-2009
	  	 Registered
	  	 09,  44

  
 14EX-10.18.3

 Exhibit 10.18.3 

OMNIBUS AMENDMENT AGREEMENT 
 This OMNIBUS AMENDMENT AGREEMENT (this “Amendment”) is entered into as of September 30, 2011, by and among Biocept, Inc., a
California corporation (the “Company”), and each of the entities identified on the signature pages hereto (each an “Investor” and collectively the “Investors”). 

RECITALS 
 A. The Company and the Investors are parties to that certain Note and Warrant Purchase Agreement, dated as of February 1, 2011, as amended on July 1, 2011 and August 1, 2011 (as
amended, the “Purchase Agreement”). 
 B. Pursuant to the Purchase
Agreement the Company issued the following Secured Convertible Promissory Notes (collectively, the “Outstanding Notes”): 
  

	 	(i)	Secured Convertible Promissory Note, dated February 1, 2011, issued to The Reiss Family GST Exempt Marital Deduction Trust, in the principal amount of $1,000,000;

  

	 	(ii)	Secured Convertible Promissory Note, dated March 1, 2011, issued to The Reiss Family Survivor’s Trust UDT dated December 19, 1988, in the principal
amount of $1,000,000; 

  

	 	(iii)	Secured Convertible Promissory Note, dated April 1, 2011, issued to The Reiss Family GST Exempt Marital Deduction Trust, in the principal amount of $1,000,000;

  

	 	(iv)	Secured Convertible Promissory Note, dated May 2, 2011, issued to The Reiss Family Survivor’s Trust UDT dated December 19, 1988, in the principal amount
of $1,000,000; 

  

	 	(v)	Secured Convertible Promissory Note, dated June 1, 2011, issued to The Reiss Family GST Exempt Marital Deduction Trust, in the principal amount of $1,000,000;

  

	 	(vi)	Secured Convertible Promissory Note, dated July 1, 2011, issued to The Reiss Family Survivor’s Trust UDT dated December 19, 1988, in the principal amount
of $1,000,000; 

  

	 	(vii)	Secured Convertible Promissory Note, dated August 1, 2011, issued to The Reiss Family Survivor’s Trust UDT dated December 19, 1988, in the principal
amount of $1,000,000; and 

  

	 	(viii)	Secured Convertible Promissory Note, dated September 12, 2011, issued to The Reiss Family Survivor’s Trust UDT dated December 19, 1988, in the principal
amount of $1,000,000. 

  
 1. 

 C. The Company and the Investors are parties to that certain Subordinated Security
Agreement, dated as of February 1, 2011 (the “Security Agreement”), pursuant to which the Company granted the Investors a subordinated security interest in certain assets of the Company as described therein. 

D. The Company and the Investors desire to amend the Outstanding Notes to provide that the Maturity Date (as defined in the
Outstanding Notes) of each Outstanding Note shall be December 31, 2012. 
 E. Section 14 of the Outstanding
Notes provides that each Outstanding Note may be amended with the written consent of the Company and each Investor. 
 F.
The Company is currently contemplating offering additional Secured Convertible Promissory Notes (collectively, the “Additional Notes”) to investors pursuant to the Purchase Agreement, and the
Company and the Investors desire to amend the Purchase Agreement to provide that the Additional Notes shall mature on December 31, 2012. 
 G. Section 6.7 of the Purchase Agreement may be amended with the written consent of the Company and the holders of at least a majority in interest of the outstanding Securities (as defined in
the Purchase Agreement). 
 H. To induce additional investors to purchase the Additional Notes, the Company and the
Investors desire to amend the Security Agreement to provide that purchasers of the Additional Notes shall be made a party to the Security Agreement, to grant such persons or entities a subordinated security interest in certain assets of the Company
as described therein. 
 I. Section 11.1 of the Security Agreement may be amended with the written consent of the
Company and each Secured Party (as defined in the Security Agreement). 
 AGREEMENT 

In exchange for other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties agree as
follows: 
 1. Amendment to Outstanding Notes. Section 4.1 of each of the Outstanding Notes is hereby amended and
restated in its entirety as set forth below: 
 “4.1 Maturity Date. This Note and all unpaid
principal and accrued interest outstanding under this Note (the “Conversion Amount”) shall be due and payable on December 31, 2012 (the “Maturity Date”); provided, however,
that the Maturity Date (i) may be extended for two successive three month periods upon the written consent of the Investor and (ii) shall be accelerated upon the occurrence of an Event of Default (defined below).” 

2. Amendment to Purchase Agreement. Exhibit A of the Purchase Agreement shall be amended and restated to read in its entirety as
set forth on Exhibit A hereto. 

  
 2. 

 3. Amendment to Security Agreement. A new Section 11.5 is hereby added to the
Security Agreement as set forth below: 
 “11.5 Additional Parties. Notwithstanding anything to the
contrary contained herein, if the Company shall issue additional Notes pursuant to the Purchase Agreement, any purchaser of such Notes shall become a party to this Security Agreement by executing and delivering an additional counterpart signature
page to this Security Agreement and shall be deemed a “Secured Party” and a party hereunder.” 

4. Miscellaneous. 
 (a) This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile or
electronic signatures shall be as effective as original signatures. 
 (b) Except as expressly modified by this
Amendment, the Purchase Agreement, the Outstanding Notes and the Security Agreement shall remain unmodified and in full force and effect. 
 (c) This Amendment shall be governed by and construed under the laws of the State of California as applied to agreements among California residents, made and to be performed entirely within the
State of California without giving effect to its conflicts of laws principles. 
 [REMAINDER OF
PAGE INTENTIONALLY LEFT BLANK] 

  
 3. 

 IN WITNESS WHEREOF, the parties hereto
have executed this OMNIBUS AMENDMENT AGREEMENT as of the date set forth in the first paragraph above. 

 

			
	 COMPANY:
  

BIOCEPT, INC.

a California corporation

		
	By:	 	/s/ William Kachioff
	 Name:
	 	William Kachioff
	 Title:
	 	CFO

 IN WITNESS WHEREOF, the parties hereto
have executed this OMNIBUS AMENDMENT AGREEMENT as of the date set forth in the first paragraph above. 

 

			
	INVESTORS:
	
	 THE REISS FAMILY GST EX MARITAL

DEDUCTION TRUST UDT 12/19/1988:

		
	 By:
	 	/s/ Claire K. T. Reiss
	 Name:
	 	CLAIRE K. T. REISS
	 Title:
	 	Trustee

  

			
	 THE REISS FAMILY SURVIVOR’S
TRUST
 UDT DATED DECEMBER 19, 1988:

		
	By:	 	/s/ Claire K. T. Reiss
	Name:	 	CLAIRE K. T. REISS
	Title:	 	Trustee

 EXHIBIT A 

FORM OF SECURED CONVERTIBLE PROMISSORY NOTE

 [Incorporated by reference to Exhibit 10.18.6 of the issuer’s Form S-1 registration statement filed September 23,
2013.]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00223-of-00352.parquet"}]]